255 related articles for article (PubMed ID: 27228467)
1. Structure-Activity Relationship of (18)F-Labeled Phosphoramidate Peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-Targeted Inhibitor Analogues for PET Imaging of Prostate Cancer.
Dannoon S; Ganguly T; Cahaya H; Geruntho JJ; Galliher MS; Beyer SK; Choy CJ; Hopkins MR; Regan M; Blecha JE; Skultetyova L; Drake CR; Jivan S; Barinka C; Jones EF; Berkman CE; VanBrocklin HF
J Med Chem; 2016 Jun; 59(12):5684-94. PubMed ID: 27228467
[TBL] [Abstract][Full Text] [Related]
2. A high-affinity [(18)F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer.
Ganguly T; Dannoon S; Hopkins MR; Murphy S; Cahaya H; Blecha JE; Jivan S; Drake CR; Barinka C; Jones EF; VanBrocklin HF; Berkman CE
Nucl Med Biol; 2015 Oct; 42(10):780-7. PubMed ID: 26169882
[TBL] [Abstract][Full Text] [Related]
3. Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer.
Lapi SE; Wahnishe H; Pham D; Wu LY; Nedrow-Byers JR; Liu T; Vejdani K; VanBrocklin HF; Berkman CE; Jones EF
J Nucl Med; 2009 Dec; 50(12):2042-8. PubMed ID: 19910433
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of constrained phosphoramidate inhibitors of prostate-specific membrane antigen.
Ley CR; Beattie NR; Dannoon S; Regan M; VanBrocklin H; Berkman CE
Bioorg Med Chem Lett; 2015 Jun; 25(12):2536-9. PubMed ID: 25956413
[TBL] [Abstract][Full Text] [Related]
5. Targeting PSMA with a Cu-64 Labeled Phosphoramidate Inhibitor for PET/CT Imaging of Variant PSMA-Expressing Xenografts in Mouse Models of Prostate Cancer.
Nedrow JR; Latoche JD; Day KE; Modi J; Ganguly T; Zeng D; Kurland BF; Berkman CE; Anderson CJ
Mol Imaging Biol; 2016 Jun; 18(3):402-10. PubMed ID: 26552656
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and pre-clinical evaluation of a new class of high-affinity
Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991
[TBL] [Abstract][Full Text] [Related]
7. Phase I Study of CTT1057, an
Behr SC; Aggarwal R; VanBrocklin HF; Flavell RR; Gao K; Small EJ; Blecha J; Jivan S; Hope TA; Simko JP; Kurhanewicz J; Noworolski SM; Korn NJ; De Los Santos R; Cooperberg MR; Carroll PR; Nguyen HG; Greene KL; Langton-Webster B; Berkman CE; Seo Y
J Nucl Med; 2019 Jul; 60(7):910-916. PubMed ID: 30464040
[TBL] [Abstract][Full Text] [Related]
8. The molecular pruning of a phosphoramidate peptidomimetic inhibitor of prostate-specific membrane antigen.
Wu LY; Anderson MO; Toriyabe Y; Maung J; Campbell TY; Tajon C; Kazak M; Moser J; Berkman CE
Bioorg Med Chem; 2007 Dec; 15(23):7434-43. PubMed ID: 17869524
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M
J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127
[TBL] [Abstract][Full Text] [Related]
10. Phosphoramidate derivatives of hydroxysteroids as inhibitors of prostate-specific membrane antigen.
Wu LY; Do JC; Kazak M; Page H; Toriyabe Y; Anderson MO; Berkman CE
Bioorg Med Chem Lett; 2008 Jan; 18(1):281-4. PubMed ID: 18023582
[TBL] [Abstract][Full Text] [Related]
11.
Choy CJ; Ling X; Geruntho JJ; Beyer SK; Latoche JD; Langton-Webster B; Anderson CJ; Berkman CE
Theranostics; 2017; 7(7):1928-1939. PubMed ID: 28638478
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Evaluation and Pilot Clinical Study of Al
Liu T; Liu C; Xu X; Liu F; Guo X; Li N; Wang X; Yang J; Yang X; Zhu H; Yang Z
J Nucl Med; 2019 Sep; 60(9):1284-1292. PubMed ID: 30796170
[TBL] [Abstract][Full Text] [Related]
13. Novel multifunctional
Kwon YD; Lee JY; La MT; Lee SJ; Lee SH; Park JH; Kim HK
Eur J Med Chem; 2020 Mar; 189():112099. PubMed ID: 32014792
[TBL] [Abstract][Full Text] [Related]
14. Development of
Potemkin R; Strauch B; Kuwert T; Prante O; Maschauer S
Mol Pharm; 2020 Mar; 17(3):933-943. PubMed ID: 32011889
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Evaluation of
Cardinale J; Schäfer M; Benešová M; Bauder-Wüst U; Leotta K; Eder M; Neels OC; Haberkorn U; Giesel FL; Kopka K
J Nucl Med; 2017 Mar; 58(3):425-431. PubMed ID: 27789722
[TBL] [Abstract][Full Text] [Related]
16. [(18)F]Fluoroethyl Triazole Substituted PSMA Inhibitor Exhibiting Rapid Normal Organ Clearance.
Chen Y; Lisok A; Chatterjee S; Wharram B; Pullambhatla M; Wang Y; Sgouros G; Mease RC; Pomper MG
Bioconjug Chem; 2016 Jul; 27(7):1655-62. PubMed ID: 27270097
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and evaluation of novel prostate-specific membrane antigen-targeted aryl [
Wang Z; Zhu B; Jiang F; Chen X; Wang G; Ding N; Song S; Xu X; Zhang W
Bioorg Med Chem; 2024 May; 106():117753. PubMed ID: 38749342
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer.
Harada N; Kimura H; Onoe S; Watanabe H; Matsuoka D; Arimitsu K; Ono M; Saji H
J Nucl Med; 2016 Dec; 57(12):1978-1984. PubMed ID: 27417647
[TBL] [Abstract][Full Text] [Related]
19. A Structure-Activity Relationship Study of Bimodal BODIPY-Labeled PSMA-Targeting Bioconjugates.
Stemler T; Hoffmann C; Hierlmeier IM; Maus S; Krause E; Ezziddin S; Jung G; Bartholomä MD
ChemMedChem; 2021 Aug; 16(16):2535-2545. PubMed ID: 33905162
[TBL] [Abstract][Full Text] [Related]
20. Validation of a [Al
Al-Momani E; Israel I; Samnick S
Appl Radiat Isot; 2017 Dec; 130():102-108. PubMed ID: 28950199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
